BCM
IMRX icon

Bridgeway Capital Management’s Immuneering IMRX Stock Holding History

Bridgeway Capital Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$623K Sell
118,149
-2,300
-2% -$11.8K 0.01% 787
2025
Q4 		$793K Hold
120,449
– – 0.02% 746
2025
Q3 		$843K Buy
120,449
+25,000
+26% +$130K 0.02% 727
2025
Q2 		$322K Buy
95,449
+35,000
+58% +$60K 0.01% 853
2025
Q1 		$91.9K Buy
60,449
+9,100
+18% +$16.5K ﹤0.01% 1051
2024
Q4 		$113K Buy
51,349
+22,400
+77% +$46.4K ﹤0.01% 1097
2024
Q3 		$72.1K Sell
28,949
-25,000
-46% -$36.4K ﹤0.01% 1189
2024
Q2 		$69.1K Sell
53,949
-60,100
-53% -$98.8K ﹤0.01% 1193
2024
Q1 		$330K Buy
114,049
+75,000
+192% +$420K 0.01% 1019
2023
Q4 		$287K Hold
39,049
– – 0.01% 1068
2023
Q3 		$300K Hold
39,049
– – 0.01% 1008
2023
Q2 		$396K Hold
39,049
– – 0.01% 970
2023
Q1 		$379K Buy
39,049
+4,100
+12% +$23.3K 0.01% 951
2022
Q4 		$170K Hold
34,949
– – ﹤0.01% 1125
2022
Q3 		$500K Hold
34,949
– – 0.01% 897
2022
Q2 		$189K Buy
+34,949
New +$186K ﹤0.01% 1100

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bridgeway Capital Management's IMRX Position: Q1 2026 in Review

Bridgeway Capital Management reduced its Immuneering (IMRX) stake by 1.9% in Q1 2026, selling an estimated $11.8K and leaving 118,149 shares worth $623K. The position accounts for 0.01% of the portfolio, ranked #787.

Bridgeway Capital Management first reported a position in IMRX in Q2 2022 and has held it in 16 quarters since. The position peaked at $843K in Q3 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Bridgeway Capital Management held 118,149 shares of Immuneering worth $623K as of Q1 2026.
  • Bridgeway Capital Management sold 2,300 Immuneering shares in Q1 2026, an estimated $11.8K.
  • Immuneering made up 0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #787 holding.
  • Bridgeway Capital Management first reported a position in Immuneering in Q2 2022 and has held it in 16 quarters since.
  • Bridgeway Capital Management's Immuneering position peaked at $843K in Q3 2025.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.